Earlier this month, diffuse intrinsic pontine glioma (DIPG) researchers from several pediatric hospitals around the country gathered in Boston to share their innovative ideas.
Displaying 41-50 of 69 results matching:
The Doris Duke Charitable Foundation announced the six projects receiving approximately $5 million through the second Sickle Cell Disease/Advancing Cures grant competition.
The peptides, folded into specific three-dimensional shapes using chemical “staples” for reinforcement, kill multidrug resistant bacteria but don’t harm red blood cells or other normal tissues.
The ASH Mentor Award recognizes hematologists who have excelled in mentoring trainees and colleagues.
U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new 2019-20 Best Children’s Hospitals rankings.
Warren is an internationally recognized expert in pediatric neuro-oncology. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery.
Vrooman will share the abstract at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Researchers call for expanding children’s access to experimental cancer therapies
Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.
Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases, sickle cell disease and beta thalassemia, applying CRISPR-Cas9 gene editing to patients' own blood stem cells.